Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported strong Q1 2024 financial results and updates on its retinal disease treatment pipeline. With $31.3 million in cash, Kiora is well-positioned to advance KIO-301 and KIO-104 into mid-stage clinical trials. The partnership with Théa Open Innovation (TOI) allows for efficient capital allocation. KIO-301 targets inherited retinal disorders, while KIO-104 addresses retinal inflammatory diseases. Positive milestones include successful Phase 1 trials and a strategic partnership with TOI. Financially, Kiora ended Q1 2024 with $31.3 million in cash, $16 million in revenue, and a net income of $13.5 million.
Kiora Pharmaceuticals (NASDAQ: KPRX) will be presenting at The Citizens JMP Life Sciences Conference on May 14th, 2024. Investors can access the online presentation live on the company's website and replay it for 90 days.
Kiora Pharmaceuticals released additional clinical data for KIO-301, a small molecule photoswitch, showing a significant increase in brain activity in the visual cortex of patients with retinitis pigmentosa. The data from the ABACUS-1 trial indicated improvements in visual field, visual acuity, and functional vision, along with an increase in neural activity that aligns with these improvements. The results were presented at the ARVO annual meeting by Professor Robert James Casson, supporting the drug's potential to restore vision.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.